Sector News

Nobel Prize in chemistry awarded to biotech founder Bertozzi, two others

October 8, 2022
Life sciences

Carolyn Bertozzi, a Stanford professor and serial biotech founder, has been awarded this year’s Nobel Prize in chemistry along with two other scientists, the Royal Swedish Academy of Sciences announced Wednesday.

She shares her prize with Morten Meldal, of the University of Copenhagen in Denmark, and K. Barry Sharpless, a former Nobel prize winner from the Scripps Research Institute in California. Meldal and Sharpless pioneered the concept of “click chemistry,” an idea describing how molecular building blocks snap together in chemical reactions.

Bertozzi took their work one step further, developing “bioorthogonal” click reactions that work inside living cells and don’t disrupt the cell’s normal chemistry. Her approach is used globally to map out cells and track biological processes, the academy said, and is behind targeted cancer treatments now being developed.

Bertozzi has also made a name for herself within the biotech industry, co-founding at least seven companies within the past 12 years. According to an interview with C&EN, her entrepreneurial push came when one of her graduate students asked for guidance in launching a company. Since then, she has continued to help launch startups based on technologies coming out of her laboratory at Stanford. The biotechs share a common foundation built on her work mapping sugar molecules called glycans that are found on cell surfaces, C&EN wrote. READ MORE

By Delilah Alvarado


comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach